Introduction {#Sec1}
============

The global prevalence of hypercholesterolemia among adults is still increased \[[@CR1]\]. Abnormal lipid levels, frequently accompanied by central obesity, high blood pressure and type 2 diabetes, have been clearly identified as a major risk factor for cardiovascular disease \[[@CR2]\]. Moreover, the high prevalence of overweight and obesity have led to the increase in lipid disorders \[[@CR3]\]. Given that pharmacological treatment may be insufficient to achieve the recommended goals for lipid concentrations, alternative lipid-lowering therapies are needed to reduce the risk of atherosclerotic cardiovascular disease \[[@CR4]--[@CR12]\].

Ursodeoxycholic acid is a primary bile acid formed in the human liver \[[@CR13], [@CR14]\]. This hydrophilic molecule has a low toxicity and is usually used at a pharmacological dose of 10--15 mg/kg/day \[[@CR14], [@CR15]\]. Ursodeoxycholic acid is widely prescribed in the treatment of several cholestatic liver diseases such as cholesterol-gallstone dissolution, primary biliary cirrhosis and cholestasis of pregnancy \[[@CR16], [@CR17]\]. Evidence suggests that the therapeutic effects of ursodeoxycholic acid are explained by an increased hydrophilicity index of the bile acid pool, stimulation of hepatocellular and ductular secretions, cytoprotection against bile acid and cytokine-induced injury, immunomodulation and anti-inflammatory effects \[[@CR17]\]. Additionally, some clinical trials have observed a significant decrease in total cholesterol levels after ursodeoxycholic acid treatment \[[@CR18]--[@CR20]\]; however, other studies found no beneficial effect of this bile acid on lipid metabolism \[[@CR21]--[@CR23]\]. Thus, the lipid-lowering activity of ursodeoxycholic acid is currently uncertain and remains to be elucidated. Therefore, the present meta-analysis of randomized placebo-controlled trials aimed to examine whether ursodeoxycholic acid treatment is an effective lipid-lowering agent.

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

This study was designed according to the guidelines of the 2009 preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement \[[@CR24]\]. In order to find randomized controlled trials evaluating the effect of ursodeoxycholic acid on lipid profile, PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched using the following search terms within titles and abstracts (also in combination with MESH terms): (ursodeoxycholic acid) AND (cholesterol OR "low-density lipoprotein" OR LDL OR LDL-C OR LDL-cholesterol OR "high-density lipoprotein" OR HDL-cholesterol OR HDL-C OR triglyceride OR hyperlipidemia OR hyperlipidemic OR dyslipidemia OR dyslipidemic OR lipid OR lipoprotein). The wild-card term "\*" was used to increase the sensitivity of the search strategy. The search was limited to articles published in English language. The literature was searched from inception to June 06, 2018.

Study selection {#Sec4}
---------------

Original studies were included if they met the following inclusion criteria: (1) being a randomized placebo-controlled trial with either parallel or cross-over design, (2) evaluating the effect of ursodeoxycholic acid on plasma/serum concentrations of lipids, and, (3) presentation of sufficient information on lipid concentrations at baseline and at the end of follow-up in each group or providing the net change values. Exclusion criteria were: (1) non-interventional trials, (2) lack of a placebo group for ursodeoxycholic acid treatment, (3) observational studies with case-control, cross-sectional or cohort design, and (4) lack of sufficient information on baseline or follow-up (or net change) lipid concentrations.

Data extraction {#Sec5}
---------------

Eligible studies were reviewed and the following data were abstracted: 1) first author's name; 2) year of publication; 3) study design; 4) number of participants in the intervention and placebo groups; 5) dose and duration of treatment with ursodeoxycholic acid; 6) age, gender and body mass index (BMI) of study participants; and 7) circulating concentrations of lipids.

Quality assessment {#Sec6}
------------------

A systematic assessment of bias in the included randomized placebo-controlled clinical trials was performed using the Cochrane criteria \[[@CR25]\]. The items used for the assessment of each study were as follows: adequacy of random sequence generation, allocation concealment, blinding of participants, personnel, outcome assessment, not addressing dropouts (incomplete outcome data), selective outcome reporting, and other potential sources of bias. According to the recommendations of the Cochrane Handbook, a judgment of "yes" indicated low risk of bias, while "no" indicated high risk of bias. Labeling an item as "unclear" indicated an unclear or unknown risk of bias.

### Quantitative data synthesis {#Sec7}

Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ) \[[@CR26]\]. Effect size was calculated as: (measure at the end of follow-up in the treatment group − measure at baseline in the treatment group) − (measure at the end of follow-up in the control group − measure at baseline in the control group). A random-effect model (using DerSimonian-Laird method) and the generic inverse variance weighting method were used to compensate for the heterogeneity of studies in terms of study design, treatment duration, and the characteristics of populations being studied \[[@CR27]\]. All units were collated as mg/dL. Standard deviations (SDs) of the mean difference were calculated using the following formula: SD = square root \[(SD~pre-treatment~)^2^ + (SD~post-treatment~)^2^ -- (2R × SD~pre-treatment~ × SD~post-treatment~)\], assuming a correlation coefficient (R) = 0.5. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI). Inter-study heterogeneity was quantitatively assessed using the *I*^*2*^ index. In order to evaluate the influence of each study on the overall effect size, a sensitivity analysis was conducted using the leave-one-out method (i.e., removing one study each time and repeating the analysis) \[[@CR28]--[@CR30]\].

Meta-regression {#Sec8}
===============

As a potential confounder of treatment response, treatment duration was entered into a random-effects meta-regression model to explore their association with the estimated effect size on plasma lipid concentrations.

Publication bias {#Sec9}
================

Evaluation of funnel plot, Begg's rank correlation and Egger's weighted regression tests were employed to assess the presence of publication bias in the meta-analysis. When there was an evidence of funnel plot asymmetry, potentially missing studies were imputed using the "trim and fill" method \[[@CR31]\].

Results {#Sec10}
=======

Flow of study selection {#Sec11}
-----------------------

Our initial search identified 795 published trials. After screening of titles and abstracts, 661 studies were excluded. Of these, 103 studies excluded for not meeting the inclusion criteria. Subsequently, 31 full-text articles were carefully reviewed for eligibility and 16 clinical trials were excluded for having no control group (*n* = 3), not presenting numerical values (*n* = 3), incomplete data on lipid parameters (*n* = 8), and treatment duration \< 1 month (*n* = 2). Finally, 15 studies were selected and included in the present meta-analysis. The detailed study selection process is presented in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow chart of the number of studies identified and included in this meta-analysis

Characteristics of included studies {#Sec12}
-----------------------------------

Data were pooled from 15 randomized placebo-controlled trials comprising a total 1370 subjects, including 735 and 635 participants in the intervention and placebo arms, respectively. Included studies were published between 1977 and 2013. The clinical trials used different doses of ursodeoxycholic acid. The range of treatment duration was from 1 month \[[@CR32], [@CR33]\] to 2 years \[[@CR18], [@CR20], [@CR23], [@CR34]--[@CR36]\]. Study design of included trials was parallel and cross-over. Selected studies enrolled subjects with primary biliary cirrhosis \[[@CR18], [@CR20], [@CR21], [@CR34]--[@CR38]\], primary hypercholesterolemia \[[@CR22]\], hypertriglyceridemia \[[@CR32]\], gallstones \[[@CR23], [@CR37]\], nonalcoholic fatty liver disease (NAFLD) \[[@CR19], [@CR39]\], nonalcoholic steatohepatitis (NASH) \[[@CR40]\], and healthy volunteers \[[@CR33]\]. Characteristics of the included clinical trials are shown in Table [1](#Tab1){ref-type="table"}.Table 1Demographic characteristics of the included studiesAuthorStudy designTarget PopulationTreatment durationnStudy groupsAge, yearsFemale (n, %)BMI, (kg/m^2^)Total cholesterol (mg/dl)LDL cholesterol (mg/dl)HDL cholesterol (mg/dl)Triglycerides\
(mg/dl)Balan et al. (1994) \[[@CR18]\]Randomized, double-blind, placebo-controlledPrimary biliary cirrhosis2 years89Placebo52 ± 9.477 (87)ND277.5 ± 106.0ND60.9 ± 20.3117.2 ± 70.788UDCA 13--15 mg/kg/day54 ± 9.380 (91)ND288.3 ± 121.7ND63.1 ± 23.6102.0 ± 50.4Battezzati et al. (1993) \[[@CR21]\]Randomized, double-blind, placebo-controlledPrimary biliary cirrhosis6 months44UDCA 500 mg/day54 ± 237 (84)ND263 ± 12ND78 ± 6ND44Placebo55 ± 241 (93)ND266 ± 13ND61 ± 5NDBraga et al. (2009) \[[@CR22]\]Randomized, double-blind, placebo-controlledPrimary hypercholeste-rolemia6 months57UDCA 13--15 mg/kg/dayNDNDND241.1 ± 30160.2 ± 2347.7 ± 12166.0 ± 7068PlaceboNDNDND244.7 ± 29160.6 ± 1948.0 ± 12180.8 ± 96Carulli et al. (1981) \[[@CR32]\]Randomized, double-blind, placebo-controlledHypertriglyce-ridemia1 month8UDCA 600 mg/day40.4^a^1 (12)ND266^a^ND38^a^405^a^8Placebo40.2^a^2 (25)ND254^a^ND39^a^249^a^Fromm et al. (1983) \[[@CR23]\]Randomized, double-blind, placebo-controlledPatients with gallstones2 years12Placebo55 ± 10.310 (82)ND201 ± 7.6NDND162 ± 30.812UDCA 400 mg/day56 ± 16.98 (67)ND227 ± 16.5NDND162 ± 20.612UDCA 800 mg/day55 ± 16.96 (50)ND248 ± 17.7NDND180 ± 32.4Gianturco et al. (2013) \[[@CR39]\]Randomized, double-blind, placebo-controlledNAFLD1 year53ALA 400 mg/day + UDCA 300 mg/day65 ± 523 (43)30 ± 2.1203 ± 8133 ± 945 ± 5123 ± 1154ALA 400 mg/day60 ± 425 (46)29.5 ± 2208 ± 9133 ± 1049 ± 6128 ± 1546UDCA 300 mg/day62 ± 621 (45)29.7 ± 1.6209 ± 10136 ± 1147 ± 7127 ± 1147Placebo61 ± 423 (48)29.3 ± 1.3207 ± 7138 ± 1243 ± 8129 ± 9Leuschner et al. (2010) \[[@CR40]\]Randomized, double-blind, placebo-controlledNASH18 months95UDCA 23--28 mg/kg/day41.4 (18--71)^a^32 (33)ND148 ± 102NDND208 ± 11191Placebo45.0 (18--73)^a^28 (30)ND162 ± 94NDND202 ± 111Lindenthal et al. (2002) \[[@CR33]\]Randomized, placebo-controlled, cross-overHealthy volunteers1 month20Overall19--38^b^5 (25)ND20UDCA 750 mg/day186 ± 24NDNDND20Placebo186 ± 19NDNDNDMéndez-Sánchez et al. (2004) \[[@CR19]\]Randomized, double-blind, placebo-controlledNAFLD6 weeks14UDCA 1200 mg/day39.7 ± 814 (100)34.2 ± 4.2196.1 ± 36.7NDNDND13Placebo37.8 ± 813 (100)33.3 ± 1.6177.7 ± 29.3NDNDNDMiettinen et al. (1995) \[[@CR20]\]Randomized, double-blind, placebo-controlledPrimary biliary cirrhosis2 years23UDCA 12--15 mg/kg/day50 ± 918 (78)24.1 ± 2.8250 ± 122138 ± 3965 ± 19ND22Placebo57 ± 1421 (95)24.8 ± 3.7226 ± 76131 ± 2151 ± 26NDNakagawa et al. (1977) \[[@CR37]\]Randomized, double-blind, placebo-controlledPatients with gallstones6 months13PlaceboNDNDND196 ± 30NDND120 ± 3316UDCA 150 mg/dayNDNDND192 ± 41NDND110 ± 3715UDCA 600 mg/dayNDNDND193 ± 29NDND143 ± 59Parés et al. (2000) \[[@CR34]\]Randomized, double-blind, placebo-controlledPrimary biliary cirrhosis2 years99UDCA 14--16 mg/kg/day57.4 ± 8.992 (92)ND276 ± 89NDNDND93Placebo53.5 ± 9.687 (93)ND276 ± 86NDNDNDPoupon et al. (1990) \[[@CR35]\]Randomized, double-blind, placebo-controlledPrimary biliary cirrhosis6 months70UDCA 13--15 mg/kg/day55 ± 1166 (94)ND282 ± 73NDNDND68Placebo58 ± 960 (89)ND266 ± 65NDNDNDPoupon et al. (1993) \[[@CR38]\]Randomized, double-blind, placebo-controlledPrimary biliary cirrhosis2 years17UDCA 13--15 mg/kg/day55 ± 12NDND289 ± 66155 ± 5244 ± 1793 ± 3216Placebo58 ± 8NDND273 ± 36134 ± 3841 ± 14102 ± 49Vuoristo et al. (1995) \[[@CR36]\]Randomized, double-blind, placebo-controlledPrimary biliary cirrhosis2 years31Placebo57^a^27 (87)24^a^278 ± 105189 ± 8461 ± 21106 ± 4830UDCA 12--15 mg/kg/day52^a^22 (73)24^a^251 ± 86158 ± 6458 ± 42115 ± 49Values are expressed as mean ± SD*Abbreviations*: *ND* no data, *BMI* body mass index, *IQR* interquartile range^a^Mean only^b^Range

Risk of bias assessment {#Sec13}
-----------------------

According to the Cochrane criteria, most of included studies showed insufficient information about random sequence generation and one study had a high risk of bias \[[@CR38]\]. With respect to allocation concealment, several trials exhibited limited information. Regarding blinding of participants, personnel and outcome assessors, several studies revealed lack of information and one trial presented high risk of bias \[[@CR33]\]. Finally, all the evaluated trials had low risk of bias for incomplete outcome data and selective outcome reporting. Details for the risk of bias assessment is presented in Table [2](#Tab2){ref-type="table"}.Table 2Quality of bias assessment of the included studies according to the Cochrane guidelinesStudySequence generationAllocation concealmentBlinding of participants, personnel and outcome assessorsIncomplete outcome dataSelective outcome reportingOther sources of biasBalan et al. (1994) \[[@CR18]\]UULLLUBattezzati et al. (1993) \[[@CR21]\]LLLLLLBraga et al. (2009) \[[@CR22]\]UUULLUCarulli et al. (1981) \[[@CR32]\]UUULLUFromm et al. (1983) \[[@CR23]\]UUULLUGianturco et al. (2013) \[[@CR39]\]LLULLULeuschner et al. (2010) \[[@CR40]\]UUULLULindenthal et al. (2002) \[[@CR33]\]UUHLLUMéndez-Sánchez et al. (2004) \[[@CR19]\]LLULLUMiettinen et al. (1995) \[[@CR20]\]UUULLUNakagawa et al. (1977) \[[@CR37]\]ULLLLUParés et al. (2000) \[[@CR34]\]ULLLLUPoupon et al. (1990) \[[@CR35]\]UUULLUPoupon et al. (1993) \[[@CR38]\]HUULLUVuoristo et al. (1995) \[[@CR36]\]UUULLU*L* low risk of bias, *H* high risk of bias, *U* unclear risk of bias

Effect of ursodeoxycholic acid on lipids {#Sec14}
----------------------------------------

Meta-analysis of 20 treatment arms revealed a significant reduction of total cholesterol following ursodeoxycholic acid treatment (WMD: − 13.85 mg/dL, 95% CI: -21.45, − 6.25, *p* \< 0.001). This effect size was robust in the sensitivity analysis **(**Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}**).** Nonetheless, other lipid indices including LDL-C (WMD: -6.66 mg/dL, 95% CI: -13.99, 0.67, *p* = 0.075), TG (WMD: -1.42 mg/dL, 95% CI: -7.51, 4.67, *p* = 0.648) and HDL-C (WMD: -0.18 mg/dL, 95% CI: -5.23, 4.87, *p* = 0.944) were not found to be significantly altered by ursodeoxycholic acid administration (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}).Fig. 2Forest plot displaying the weighted mean difference and 95% confidence intervals for the impact of treatment with UDCA on lipid indicesFig. 3Leave-one-out sensitivity analysis for the meta-analysis of UDCA's effects on plasma lipid indices

In patients with primary biliary cirrhosis, ursodeoxycholic acid reduced total cholesterol (WMD: − 29.86 mg/dL, 95% CI: -47.39, − 12.33, *p* = 0.001) and LDL-C (WMD: -37.27 mg/dL, 95% CI: -54.16, − 20.38, *p* \< 0.001) concentrations without affecting TG (WMD: 11.24 mg/dL, 95% CI: -1.15, 23.62, *p* = 0.075) and HDL-C (WMD: -3.27 mg/dL, 95% CI: -8.75, 2.22, *p* = 0.243) levels (Fig. [4](#Fig4){ref-type="fig"})**.**Fig. 4Forest plot displaying the weighted mean difference and 95% confidence intervals for the impact of treatment with UDCA on lipid indices in patients with primary biliary cirrhosis

Meta-regression {#Sec15}
---------------

Meta-regression analysis revealed that the effects of ursodeoxycholic acid on total cholesterol (slope: − 1.51; *p* \< 0.001), LDL-C (slope: − 1.97; *p* = 0.001) and TG (slope: 1.38; *p* = 0.004) but not HDL-C (slope: − 0.23; *p* = 0.482) concentrations were associated with treatment duration (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Meta-regression bubble plot of the association between mean changes in plasma lipids concentrations following UDCA supplementation with the duration of supplementation. The size of each circle is inversely proportional to the variance of change

Publication bias {#Sec16}
----------------

Publication bias assessment revealed asymmetric funnel plots and evidence suggestive of bias. This asymmetry was corrected by imputing potentially missing studies using "trim and fill" method (Fig. [6](#Fig6){ref-type="fig"}). Egger's regression test suggested the presence of publication bias in the meta-analyses of total cholesterol (*p* = 0.008), LDL-C (*p* = 0.003) and HDL-C (*p* = 0.026). Begg's rank correlation test suggested the presence of publication bias only in the meta-analysis of LDL-C (*p* = 0.024).Fig. 6Funnel plot detailing publication bias in the studies reporting the impact of UDCA on lipid indices. Open circles represent observed published studies while closed circles represent imputed unpublished studies using trim and fill method

Discussion {#Sec17}
==========

The present meta-analysis of randomized placebo-controlled trials examined whether ursodeoxycholic acid treatment might be an effective lipid-lowering agent. Indeed, this meta-analysis revealed a significant reduction in total cholesterol levels following ursodeoxycholic acid therapy (− 13.85 mg/dL), but the rest of parameters of lipid profile were not significantly changed.

In consistency with our findings, several clinical trials have found a significant reduction in total cholesterol concentrations after ursodeoxycholic acid administration \[[@CR18], [@CR19], [@CR39], [@CR40]\]; however, the potential mechanisms involved in the cholesterol-lowering effects of this bile acid have not been clarified. In this regard, it has been proposed that ursodeoxycholic acid may decrease the cholesterol biosynthesis by reducing the activity of hydroxymethylglutaryl-coenzime A reductase \[[@CR41], [@CR42]\]. Also, ursodeoxycholic acid decreases the dietary cholesterol absorption lowering serum cholesterol levels \[[@CR43]\]. Additionally, it has been proven that the administration of ursodeoxycholic improves hepatic function through increasing the synthesis of bille acid, cholesterol and steatosis, and decreasing the activity of farnesoid X receptor (FXR) \[[@CR44]\].

Experimental data suggested that ursodeoxycholic acid has also the ability to protect the cholangiocytes against hydrophobic bile acids by simultaneous decrease of the concentration of hydrophobic bile and reduction of the bile acid cytotoxicity \[[@CR45]\]. Besides, it has been reported that this pharmacological agent increases hepatic LDL uptake through a direct interaction with the LDL receptor \[[@CR46]\]. Furthermore, ursodeoxycholic acid was reported to be able to change the hydrophobicity index of the bile acid pool \[[@CR47], [@CR48]\]. Ursodeoxycholic acid may improve the cell resistance to reactive oxygen species, to decrease the permeability of the mitochondrial membrane and to inhibit release of hydrolytic enzymes from damaged hepatocytes \[[@CR49], [@CR50]\]. Moreover, some important genes involved in lipid uptake (*Cd36* and *Ldlr*) and hepatic lipid synthesis (PPARG, *Chrebp-a/−b*, *Acaca*, *Fasn*, *Me1*, and *Scd1*) seems to be modulated by ursodeoxycholic acid, as mecanisms of protection against hepatic fat accumulation \[[@CR51]\]. Ursodeoxycholic acid may also influence the adipose tissue through increasing triglyceride levels, and increasing the esterification and desaturation of fatty acids \[[@CR52]\].

Of particular interest is the clinically relevant decrease in TC and LDL-C specifically observed in primary biliary cirrhosis patients. This could be of particular interest given the increased coronary artery disease risk observed in patients affected by this condition \[[@CR53]\].

There are some limitations of this meta-analysis that deserve to be mentioned. First, the lipid-lowering action of ursodeoxycholic acid was not the primary outcome in almost all selected studies; hence, further clinical trials are needed in order to corroborate the hypolipidemic effect of this acid bile as primary endpoint. Second, several studies included in this meta-analysis presented insufficient information with respect to the quality of bias assessment suggesting caution in the overall quality. Third, although the selected studies were heterogeneous in terms of target population and characteristics, we tried to minimize the inter-study heterogeneity using a random-effects model. Finally, most of the trials assessed were performed on small sample sizes resulting in a limited pooled population in the overall analysis.

Conclusion {#Sec18}
==========

This meta-analysis suggests that ursodeoxycholic acid therapy might be associated with significant total cholesterol lowering. Nonetheless, these results could have been influenced by the variability, the sample size, and the quality of the studies included. Fuurther investigation is required to elucidate if observed lipid-lowering effects of ursodeoxycholic acid in patients with primary biliary cirrhosis can contribute to the prevention of cardiovascular events and whether there is any added value of using ursodeoxycholic acid as an adjunct or alternative to current or novel lipid-modifyinga gents \[[@CR54], [@CR55]\]
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